PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 27818020-9 2017 Levels of soluble IL-6 in HUVEC supernatants were significantly lower after pre-incubation with ezetimibe. Ezetimibe 96-105 interleukin 6 Homo sapiens 18-22 23013513-0 2013 Effects of simvastatin and ezetimibe on interleukin-6 and high-sensitivity C-reactive protein. Ezetimibe 27-36 interleukin 6 Homo sapiens 40-53 20880729-8 2011 Ezetimibe was associated with a significant reduction in aortic wall MMP-9 (p = 0.02) and aortic wall IL-6 (p = 0.02), associated with a reduction in plasma lipids. Ezetimibe 0-9 interleukin 6 Homo sapiens 102-106 20185740-6 2010 Compared with weight loss alone, ezetimibe plus weight loss significantly (all P < 0.05) decreased IHTG content (-18%), plasma hs-CRP (-53%), interleukin-6 (-24%), LDL cholesterol (-18%), campesterol (-59%), and apoB-100 (-14%) levels, with a significant increase in plasma lathosterol concentrations (+43%). Ezetimibe 33-42 interleukin 6 Homo sapiens 145-158 26687339-9 2016 RESULTS: The combination of ezetimibe plus rosuvastatin decreased total cholesterol, low-density lipoprotein cholesterol, hsCRP, IL-6, and MMP-9 levels at six and 12 months after treatment. Ezetimibe 28-37 interleukin 6 Homo sapiens 129-133 23062767-12 2012 CONCLUSIONS: A high simvastatin dose or the combination of a low-dose simvastatin with ezetimibe reduce to a similar extent TLR2, TLR4 membrane expression and LPS-induced IL-6 and IL-1beta production in monocytes of hypercholesterolemic patients. Ezetimibe 87-96 interleukin 6 Homo sapiens 171-175